Therapeutic efficacy and safety of potassium-competitive acid blockers for acid-related diseases:a Meta-analysis
OBJECTIVE To systematically evaluate the efficacy and safety of potassium-competitive acid blockers for acid-related diseases and provide evidence-based references for clinical dosing.METHODS Computer searches of PubMed,Scopus,Embase,Cochrane library,China National Knowledge Infrastructure(CNKI),China Biomedical Literature Database,VIP and Wanfang were conducted from database inceptions until July 2023.The literature of clinical randomized controlled trials of potassium-competitive acid blockers for treating acid-related diseases was collected.After extracting the relevant data,quality of the included literature was evaluated by the risk-of-bias assessment tool recommended by the Cochrane Systematic Evaluator's Handbook 5.1.0.The data were organized according to the inclusion and exclusion criteria.And RevMan 5.4 was utilized for Meta-analysis.RESULTS A total of 43 papers with a total of 10840 patients were recruited.During Helicobacter pylori infec-tion treatment,intention-to-treat(ITT)analysis and protocol compliant(PP),trial group had significantly higher overall eradica-tion rates than control group(87.41％vs.79.86％)[OR=1.80,95％CI(1.36,2.37),P＜0.000 01]and(89.95％vs.83.54％)[OR=1.87,95％CI(1.45,2.41),P＜0.000 01].Regarding gastroesophageal reflux treatment,clinical efficiency was higher in trial group than that in control group(66.27％vs.58.38％)[OR=1.84,95％CI(1.14,2.97),P=0.01].As for ero-sive esophagitis treatment,healing rate of erosive esophagitis was significantly higher in trial group than that in control group(94.73％vs.89.69％)[OR=2.13,95％CI(1.59,2.86),P＜0.000 01].In terms of ulcer healing,trial group was comparable to control group.The overall incidence of adverse events was significantly lower in trial group than that in control group(28.9％vs.32.05％)[OR=0.85,95％CI(0.77,0.94),P=0.000 9].CONCLUSION The efficacy and safety of potassium-competitive acid blockers for acid-related disorders are superior to those of proton pump inhibitors.
NETL
NSTL
万方数据
